{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024988","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.963029+00:00","generated_at":"2026-06-21T20:45:53.787157+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Equillium Q3 net loss $13.7M ($0.40/shr); Metacrine deal to add $35M cash","bullets":["Net loss $13.7M ($0.40/shr) vs $10.3M ($0.35) in Q3 2021; R&D $8.8M, G&A $4.5M.","Cash, equivalents and investments $44.5M as of Sep 30; pending Metacrine acquisition expected to add ~$35M cash, extending runway into 2024.","Positive interim itolizumab data in lupus nephritis: 83% achieved complete or partial response by week 28; 67% had >80% UPCR reduction.","Initiated Phase 2 study of EQ101 in alopecia areata (30 subjects) and Phase 1 study of EQ102 in celiac disease; data expected in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024988","json":"https://secwatch.observer/filing/0000950170-22-024988.json","markdown":"https://secwatch.observer/filing/0000950170-22-024988.md","text":"https://secwatch.observer/filing/0000950170-22-024988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000095017022024988/0000950170-22-024988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000095017022024988/eq-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:45:53.787157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea3abad6f5aa12ed77ec199ee45e26c892d7a211","claim":"Equillium, Inc. reported the third quarter ended September 30, 2022 results: net income $13.7 million, EPS $(0.40) per basic and diluted share.","evidence_excerpt":"Net loss for the third quarter of 2022 was $13.7 million, or $(0.40) per basic and diluted share, compared with a net loss of $10.3 million, or $(0.35) per basic and diluted share for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746466/000095017022024988/0000950170-22-024988-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$13.7 million"},{"label":"EPS","value":"$(0.40) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}